Cencora's major customers
Walgreens And Boots UK accounted for 25% of Cencora's revenue in FY 2025. 9 listed suppliers report Cencora as a customer worth 10% or more of their revenue, led by Coherus Oncology at 36%.
Get an email when Cencora's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Major customers of Cencora
Customers that Cencora named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Walgreens And Boots UK | 25% | new | 1 year | FY 2025 · filed 25 Nov 2025 |
| Evernorth Health Services | 13% | new | 1 year | FY 2025 · filed 25 Nov 2025 |
Formerly disclosed
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Walgreens Boots Alliance | 26% | last FY 2024 | 4 years | FY 2024 · filed 26 Nov 2024 |
| Express Scripts | 13% | last FY 2024 | 4 years | FY 2024 · filed 26 Nov 2024 |
Suppliers that depend on Cencora
Listed companies whose annual report names Cencora as a customer worth 10% or more of their revenue. If Cencora cuts orders or switches supplier, these are the companies that feel it.
| Supplier | Its revenue from this company | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Coherus OncologyCHRS | 36% | ▼ from 43% | 2 years | FY 2025 · filed 9 Mar 2026 |
| Bristol Myers SquibbBMY | 29% | from 29% | 5 years | FY 2025 · filed 11 Feb 2026 |
| ExelixisEXEL | 22% | from 18% | 4 years | FY 2026 · filed 10 Feb 2026 |
| Amphastar PharmaceuticalsAMPH | 22% | from 20% | 5 years | FY 2025 · filed 26 Feb 2026 |
| Gilead SciencesGILD | 21% | from 21% | 5 years | FY 2025 · filed 24 Feb 2026 |
| Rigel PharmaceuticalsRIGL | 19% | from 20% | 4 years | FY 2025 · filed 3 Mar 2026 |
| Bausch Health CompaniesBHC | 18% | from 19% | 5 years | FY 2025 · filed 19 Feb 2026 |
| ArdelyxARDX | 17% | from 16% | 4 years | FY 2025 · filed 19 Feb 2026 |
| PfizerPFE | 16% | from 17% | 4 years | FY 2025 · filed 26 Feb 2026 |
Formerly disclosed
| Supplier | Its revenue from this company | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Akebia TherapeuticsAKBA | 19% | last FY 2024 | 3 years | FY 2024 · filed 26 Feb 2026 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API